Impact of Empagliflozin on Serum Calcium and Phosphate in Heart Failure
Abstract
Background: Alterations in serum calcium (Ca2+) and phosphate (Pi) balance have been associated with poor outcomes in heart failure (HF). However, these data are derived mostly from small observational studies. Moreover, the impact of SGLT2 inhibitors on Ca2+and Pi levels has not been explored in large, randomized HF trials.
Aims: Using EMPEROR (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction-Pooled) data, we aim to study the prognostic associations of serum Ca2+ and Pi in patients with HF and to study the impact of empagliflozin on Ca2+ and Pi levels.
Methods: EMPEROR-Pooled (N = 9718) was used to create serum Ca2+ and Pi categories (quintiles, Q). Cox and mixed-effects models were used.
Results: Mean Ca2+ levels were 2.35 ± 0.12 mmol/L and Pi 1.14 ± 0.18 mmol/L. Compared to patients with higher Ca2+ levels (Q5, mean 2.5 ± 0.1 mmol/L), those with lower Ca2+ (Q1, mean 2.2 ± 0.1 mmol/L) presented more peripheral edema and higher NT-proBNP levels (P 2+ was modestly associated with a higher risk of cardiovascular death or HF hospitalization. The effect of empagliflozin (vs placebo) on cardiovascular death or HF hospitalization was not influenced by serum Ca2+ levels (interaction-P > 0.1), while the mortality reduction rate appeared more marked among patients with higher serum Ca2+ (interaction-P = 0.08). Serum phosphate levels were not associated with outcomes and did not influence the effect of empagliflozin (interaction-P >…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 9,718 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.